SymbolCINGW
NameCINGULATE INC.
SectorHEALTH CARE
RegionNorth America
IndustryBiotechnology: Pharmaceutical Preparations
Address1901 W. 47TH PLACE, KANSAS CITY, Kansas, 66205, United States
Telephone+1 913 - 942-2300
Fax
Email
Websitehttps://www.cingulate.com
IncorporationUNDEFINED
Incorporated On
Employees
Fiscal Year
Public Since
ExchangesNASDAQ
Auditor
Audit StatusNOT PROVIDED
Reporting Status
CIK0001862150
Description

Cingulate Inc is a clinical stage biopharmaceutical company utilizing its proprietary precision timed release drug delivery platform to build and advance a pipeline of next-generation pharmaceutical products designed to improve the lives of patients suffering from frequently diagnosed conditions characterized by burdensome daily dosing regimens and suboptimal treatment outcomes.

Additional info from NASDAQ:
Cingulate Inc is a clinical stage biopharmaceutical company utilizing its proprietary precision timed release drug delivery platform to build and advance a pipeline of next-generation pharmaceutical products designed to improve the lives of patients suffering from frequently diagnosed conditions characterized by burdensome daily dosing regimens and suboptimal treatment outcomes.

2026-08-13 12:40

(30% Negative) CINGULATE INC. (CINGW) Reports Q3 2026 Financial Results

Read more
2026-08-13 12:30

Cingulate Inc. Reports Second Quarter 2026 Financial Results and Provides Update on CTx-1301 CMC Progress Towards NDA Resubmission and Commercial Readiness

Read more
2026-08-11 12:30

Cingulate Publishes Peer-Reviewed Data Demonstrating CTx-1301’s Differentiated Pharmacokinetic Profile

Read more
2026-07-30 12:30

Cingulate Announces Publication of Phase 3 ADHD Trial Results in Journal of Child and Adolescent Psychopharmacology

Read more
2026-07-23 20:05

(99% Neutral) CINGULATE INC. (CINGW) Announces New Board Appointment

Read more
2026-07-20 23:37

Director Schaffer Shane J. 🟢 acquired 295.0K shares (2 derivative) of Cingulate Inc. (CING) at $4.43 ($1.3M) Transaction Date: Jul 16, 2026 | Filing ID: 033972

Read more
2026-07-20 23:35

Downey Bryan Wade 🟢 acquired 100.0K shares (2 derivative) of Cingulate Inc. (CING) at $4.43 Transaction Date: Jul 16, 2026 | Filing ID: 033970

Read more
2026-07-20 23:32

Director Lawrence Bryan Jay 🟢 acquired 20.0K shares (1 derivative) of Cingulate Inc. (CING) at $4.43 Transaction Date: Jul 16, 2026 | Filing ID: 033968

Read more
2026-07-20 23:32

Brams Matthew 🟢 acquired 80.0K shares (2 derivative) of Cingulate Inc. (CING) at $4.43 Transaction Date: Jul 16, 2026 | Filing ID: 033967

Read more
2026-07-20 23:29

Director Hargroves Thomas Jeffrey 🟢 acquired 20.0K shares (1 derivative) of Cingulate Inc. (CING) at $4.43 Transaction Date: Jul 16, 2026 | Filing ID: 033964

Read more